Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies

Neurobiology of Aging

Volumn 35, Issue 4, 2014, Pages 926-933

  Belrose, Jillian C ^a   Masoudi, Raheleh ^a   Michalski, Bernadeta ^a   Fahnestock, Margaret ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Brain derived neurotrophic factor; Corticobasal degeneration; Nerve growth factor; Neurotrophin; Pick's disease; Post mortem brain; Progressive supranuclear palsy; Tau; Tauopathy

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PARIETAL CORTEX; PATHOPHYSIOLOGY; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TAUOPATHY; TISSUE LEVEL; WESTERN BLOTTING;

ALZHEIMER'S DISEASE; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORTICOBASAL DEGENERATION; NERVE GROWTH FACTOR; NEUROTROPHIN; PICK'S DISEASE; POST MORTEM BRAIN; PROGRESSIVE SUPRANUCLEAR PALSY; TAU; TAUOPATHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; PICK DISEASE OF THE BRAIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAU PROTEINS; TAUOPATHIES;

EID: 84891371228     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.08.029     Document Type: Article

References (61)

1. Arai T., Ikeda K., Akiyama H., Tsuchiya K., Iritani S., Ishiguro K., Yagishita S., Oda T., Odawara T., Iseki E. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 2003, 105:489-498.
2. Arancibia S., Silhol M., Mouliere F., Meffre J., Hollinger I., Maurice T., Tapia-Arancibia L. Protective effect of BDNF against beta-amyloid induced neurotoxicity invitro and invivo in rats. Neurobiol. Dis. 2008, 31:316-326.
3. Belarbi K., Burnouf S., Fernandez-Gomez F.J., Desmercieres J., Troquier L., Brouillette J., Tsambou L., Grosjean M.E., Caillierez R., Demeyer D., Hamdane M., Schindowski K., Blum D., Buee L. Loss of medial septum cholinergic neurons in THY-Tau22 mouse model: what links with tau pathology?. Curr. Alzheimer Res. 2011, 8:633-638.
4. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
5. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A 2009, 106:13594-13599.
6. Bradbury J. Hope for AD with NGF gene-therapy trial. Lancet Neurol. 2005, 4:335.
7. Burnouf S., Belarbi K., Troquier L., Derisbourg M., Demeyer D., Leboucher A., Laurent C., Hamdane M., Buee L., Blum D. Hippocampal BDNF expression in a tau transgenic mouse model. Curr. Alzheimer Res. 2012, 9:406-410.
8. Castello N.A., Green K.N., Laferla F.M. Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter Abeta or tau pathology. PLoS One 2012, 7:e39566.
9. Connor B., Young D., Yan Q., Faull R.L., Synek B., Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res. Mol. Brain Res. 1997, 49:71-81.
10. Cooper J.D., Lindholm D., Sofroniew M.V. Reduced transport of [125I]nerve growth factor by cholinergic neurons and down-regulated TrkA expression in the medial septum of aged rats. Neuroscience 1994, 62:625-629.
11. Counts S.E., Nadeem M., Wuu J., Ginsberg S.D., Saragovi H.U., Mufson E.J. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann. Neurol. 2004, 56:520-531.
12. Cowan C.M., Bossing T., Page A., Shepherd D., Mudher A. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau invivo. Acta Neuropathol. 2010, 120:593-604.
13. Fahnestock M. BDNF: The link between beta-amyloid and memory loss. Future Neurology 2011, 6:627-639.
14. Fahnestock M., Michalski B., Xu B., Coughlin M.D. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol. Cell. Neurosci. 2001, 18:210-220.
15. Fahnestock M., Scott S.A., Jette N., Weingartner J.A., Crutcher K.A. Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Brain Res. Mol. Brain Res. 1996, 42:175-178.
16. Ferrer I., Marin C., Rey M.J., Ribalta T., Goutan E., Blanco R., Tolosa E., Marti E. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J.Neuropathol. Exp. Neurol. 1999, 58:729-739.
17. Garzon D., Yu G., Fahnestock M. Anew brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J.Neurochem. 2002, 82:1058-1064.
18. Garzon D.J., Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J.Neurosci. 2007, 27:2628-2635.
19. Ginsberg S.D., Che S., Wuu J., Counts S.E., Mufson E.J. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J.Neurochem. 2006, 97:475-487.
20. Gutierrez H., Miranda M.I., Bermudez-Rattoni F. Learning impairment and cholinergic deafferentation after cortical nerve growth factor deprivation. J.Neurosci. 1997, 17:3796-3803.
21. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
22. Hock C., Heese K., Hulette C., Rosenberg C., Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 2000, 57:846-851.
23. Holsinger R.M., Schnarr J., Henry P., Castelo V.T., Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res. Mol. Brain Res. 2000, 76:347-354.
24. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
25. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in alzheimer's disease mouse models. Cell 2010, 142:387-397.
26. Janus C. Conditionally inducible tau mice-designing a better mouse model of neurodegenerative diseases. Genes. Brain and Behavior 2008, 7(suppl. 1):12-27.
27. LaFerla F.M. Pathways linking Abeta and tau pathologies. Biochem. Soc. Trans. 2010, 38:993-995.
28. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
29. Ljungberg M.C., Ali Y.O., Zhu J., Wu C.S., Oka K., Zhai R.G., Lu H.C. CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. Hum. Mol. Genet. 2012, 21:251-267.
30. Lu B. BDNF and activity-dependent synaptic modulation. Learn. Mem. 2003, 10:86-98.
31. Marcinkowski T. The diseases of Alzheimer and Pick from the viewpoint of prevention. Med. Hypotheses 1996, 46:180-182.
32. Michalski B., Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Brain Res. Mol. Brain Res. 2003, 111:148-154.
33. Morris M., Maeda S., Vossel K., Mucke L. The many faces of tau. Neuron 2011, 70:410-426.
34. Mufson E.J., Conner J.M., Kordower J.H. Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport 1995, 6:1063-1066.
35. Mufson E.J., Counts S.E., Fahnestock M., Ginsberg S.D. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr. Alzheimer Res. 2007, 4:340-350.
36. Murray B., Lynch T., Farrell M. Clinicopathological features of the tauopathies. Biochem. Soc. Trans. 2005, 33:595-599.
37. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nature Med. 2009, 15:331-337.
38. Niewiadomska G., Baksalerska-Pazera M. Age-dependent changes in axonal transport and cellular distribution of Tau 1 in the rat basal forebrain neurons. Neuroreport 2003, 14:1701-1706.
39. Niewiadomska G., Baksalerska-Pazera M., Riedel G. Altered cellular distribution of phospho-tau proteins coincides with impaired retrograde axonal transport in neurons of aged rats. Ann. N. Y. Acad. Sci. 2005, 1048:287-295.
40. Peng S., Garzon D.J., Marchese M., Klein W., Ginsberg S.D., Francis B.M., Mount H.T., Mufson E.J., Salehi A., Fahnestock M. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J.Neurosci. 2009, 29:9321-9329.
41. Peng S., Wuu J., Mufson E.J., Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J.Neurochem. 2005, 93:1412-1421.
42. Peng S., Wuu J., Mufson E.J., Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J.Neuropathol. Exp. Neurol. 2004, 63:641-649.
43. Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991, 7:695-702.
44. Pruunsild P., Kazantseva A., Aid T., Palm K., Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007, 90:397-406.
45. Reichardt L.F., Mobley W.C. Going the distance, or not, with neurotrophin signals. Cell 2004, 118:141-143.
46. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
47. Rossor M.N. Pick's disease: a clinical overview. Neurology 2001, 56:S3-S5.
48. Salehi A., Delcroix J.D., Belichenko P.V., Zhan K., Wu C., Valletta J.S., Takimoto-Kimura R., Kleschevnikov A.M., Sambamurti K., Chung P.P., Xia W., Villar A., Campbell W.A., Kulnane L.S., Nixon R.A., Lamb B.T., Epstein C.J., Stokin G.B., Goldstein L.S., Mobley W.C. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006, 51:29-42.
49. Salehi A., Delcroix J.D., Swaab D.F. Alzheimer's disease and NGF signaling. J.Neural Transm. 2004, 111:323-345.
50. Scheff S.W., Price D.A. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging 2003, 24:1029-1046.
51. Schindowski K., Belarbi K., Buee L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 2008, 7(suppl 1):43-56.
52. Scott S.A., Mufson E.J., Weingartner J.A., Skau K.A., Crutcher K.A. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J.Neurosci. 1995, 15:6213-6221.
53. Tao X., Finkbeiner S., Arnold D.B., Shaywitz A.J., Greenberg M.E. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1998, 20:709-726.
54. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
55. Tong L., Balazs R., Thornton P.L., Cotman C.W. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J.Neurosci. 2004, 24:6799-6809.
56. Tong L., Thornton P.L., Balazs R., Cotman C.W. Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J.Biol. Chem. 2001, 276:17301-17306.
57. Vossel K.A., Zhang K., Brodbeck J., Daub A.C., Sharma P., Finkbeiner S., Cui B., Mucke L. Tau reduction prevents Abeta-induced defects in axonal transport. Science 2010, 330:198.
58. Wada A., Yokoo H., Yanagita T., Kobayashi H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J.Pharmacol. Sci. 2005, 99:307-321.
59. Woolf N.J., Milov A.M., Schweitzer E.S., Roghani A. Elevation of nerve growth factor and antisense knockdown of TrkA receptor during contextual memory consolidation. J.Neurosci. 2001, 21:1047-1055.
60. Yamada K., Mizuno M., Nabeshima T. Role for brain-derived neurotrophic factor in learning and memory. Life Sci. 2002, 70:735-744.
61. Yoshida M. Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 2006, 26:457-470.